Dayvigo (Lemborexant) Prescribing Information 2025 PDF Guide
Dayvigo FDA label covers 5mg/10mg dosing, hepatic impairment caps, complex sleep behavior boxed warning, and driving impairment data from 2020-2026 revisions.
Lemborexant: Regulatory History
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
2topic areas covered
Jul 14, 2025latest review
Lemborexant: Regulatory History library
Showing 4 of 4 clinical reviews.
Dayvigo (Lemborexant): EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA evaluated and regulated Dayvigo (lemborexant), including approval timelines, label differences, scheduling, and post-market safety requirements.
Lemborexant EMA Approval Status and Global Markets
Lemborexant (Dayvigo) is approved by the EMA plus FDA, Japan, Canada and Australia, with Schedule IV status and 5mg/10mg doses in the US.
Lemborexant Updates: FDA Status, Label, and Pipeline
Lemborexant (Dayvigo) is FDA-approved for insomnia; SUNRISE-3 data may support a new indication for dementia-related sleep-wake disorder. See current status.